Term
|
Definition
Colcrys®
MOA: Inhibits lactic acid production, decreases uric acid deposition, reduces phagocytosis, and decreases inflammation
Dose: 1.2 mg followed by 0.6 mg every 1-2 hours until symptoms resolve, max=8 mg
Colchicine |
|
|
Term
Xanthine Oxidase Inhibitors |
|
Definition
Allopurinol (Zyloprim®)
Febuxostat (Uloric®)
|
|
|
Term
|
Definition
Zyloprim®
MOA: Inhibits xanthine oxidase, impairs the conversion of xanthine to uric acid, thereby decreasing the production of uric acid
Dose: 100-800 mg daily
Xanthine Oxidase Inhibitor |
|
|
Term
|
Definition
Uloric®
MOA: Inhibits xanthine oxidase, impairs the conversion of xanthine to uric acid, thereby decreasing the production of uric acid
Dose: 40-80 mg daily
Xanthine Oxidase Inhibitor |
|
|
Term
|
Definition
Sulfinpyrazone (Anturane®)
Probenecid (Benemid®) |
|
|
Term
|
Definition
Anturane®
MOA: Increases the renal clearance of uric acid by inhibiting tubular reabsorption
Dose: 50-800 mg daily in 2 divided doses
Uricosuric Agents |
|
|
Term
|
Definition
Benemid®
MOA: Increases the renal clearance of uric acid by inhibiting tubular reabsorption
Dose: 250-2000 mg daily in 2 divided doses
Uricosuric Agents |
|
|
Term
|
Definition
Indocin®
MOA: Inhibits the inflammation in the joints caused by the deposition of uric acid to reduce the pain
Dose: 50 mg TID
NSAID |
|
|
Term
|
Definition
Rasburicase (Elitek®)
Pegloticase (Krystexxa®) |
|
|
Term
|
Definition
Elitek®
MOA: Converts uric acid to allantoin which is a water soluble compound
Dose: 20 mg/kg IV for 30 minutes for 5 days
BBW: May cause methhemoglobinemia (a condition where the hemoglobin cannot carry oxygen), glucose-6-phosphate dehydrogenase deficiency, and anaphylaxis
Uricase Enzymes |
|
|
Term
|
Definition
Krystexxa®
MOA: Converts uric acid to allantoin which is a water soluble compound
Dose: 8 mg IV every 2 weeks
BBW: Anaphylactic reaction
Uricase Enzymes |
|
|
